POOLED ANALYSIS OF OBJECTIVE COUGH FREQUENCY IN PARTICIPANTS WITH CHRONIC COUGH TREATED WITH GEFAPIXANT IN TWO PHASE 3 CLINICAL TRIALS (COUGH-1 AND COUGH-2)

被引：1
|
作者：
Smith, J. A. [1 ,2 ]
Morice, A. [3 ]
McGarvey, L. [4 ]
Pavord, I. [5 ]
Birring, S. S. [6 ]
Dicpinigaitis, P. [7 ,8 ]
Iskold, B. [9 ]
Li, Q. [9 ]
Tzontcheva, A. [9 ]
La Rosa, C. [9 ]
Muccino, D. [9 ]
机构：
[1] Univ Manchester, Div Infect, Immun & Resp Med, Manchester, Lancs, England
[2] Manchester Univ NHS Trust, Div Infect, Immun & Resp Med, Manchester, Lancs, England
[3] Hull York Med Sch, Cottingham, England
[4] Queens Univ Belfast, Wellcome Wolfson Inst Expt Med, Belfast, Antrim, North Ireland
[5] Univ Oxford, Nuffield Dept Med, Oxford NIHR Resp BRC, Oxford, England
[6] Kings Coll London, Sch Basic & Med Biosci, Fac Life Sci & Med, Ctr Human & Appl Physiol Sci, London, England
[7] Albert Einstein Coll Med, Bronx, NY USA
[8] Montefiore Med Ctr, 111 E 210th St, Bronx, NY 10467 USA
[9] Merck & Co Inc, Kenilworth, NJ USA
来源：
THORAX | 2021年 / 76卷
关键词：
D O I：
10.1136/thorax-2021-BTSabstracts.171
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
P61
引用
收藏
页码：A99 / A100
页数：2
相关论文
共 50 条
  • [1] Objective Cough Frequency with Gefapixant in Chronic Cough: A Pooled Analysis of Two Phase 3 Randomized, Controlled Clinical Trials (COUGH-1 and COUGH-2)
    Smith, J.
    Morice, A. H.
    Mcgarvey, L.
    Pavord, I. D.
    Birring, S. S.
    Dicpinigaitis, P.
    Iskold, B.
    Li, Q.
    Tzontcheva, A.
    La Rosa, C.
    Muccino, D.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (09)
  • [2] Responder analysis of Leicester Cough Questionnaire domains from phase 3 trials of gefapixant (COUGH-1/COUGH-2)
    Birring, Surinder S.
    Dicpinigaitis, Peter
    Mcgarvey, Lorcan
    Morice, Alyn H.
    Smith, Jaclyn A.
    Li, Qing
    La Rosa, Carmen
    Nguyen, Allison Martin
    EUROPEAN RESPIRATORY JOURNAL, 2024, 64
  • [3] Cough Triggers and Symptoms Among Patients with Refractory or Unexplained Chronic Cough in Two Phase 3 Trials of the P2X3 Receptor Antagonist Gefapixant (COUGH-1 and COUGH-2)
    Morice, Alyn
    Birring, Surinder
    Dicpinigaitis, Peter
    McGarvey, Lorcan
    Pavord, Ian
    Smith, Jaclyn
    La Rosa, Carmen
    Li, Qing
    Nguyen, Allison Martin
    Schelfhout, Jonathan
    Tzontcheva, Anjela
    Muccino, David
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2021, 147 (02) : AB61 - AB61
  • [4] Dose Selection for Two, Phase 3, Randomized Controlled Trials (Cough-1 and Cough-2) in Refractory or Unexplained Chronic Cough
    Hussain, A.
    La Rosa, C.
    Tershakovec, A.
    Kleijn, H. Jan
    Muccino, D.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [5] The Cough Severity Diary in a pooled analysis of two, phase 3 trials of gefapixant in chronic cough
    Birring, Surinder S.
    Smith, Jaclyn A.
    Morice, Alyn
    Pavord, Ian
    Dicpinigaitis, Peter V.
    Mcgarvey, Lorcan
    Tzontcheva, Anjela
    Li, Qing
    Nguyen, Allison Martin
    Schelfhout, Jonathan
    Muccino, David
    La Rosa, Carmen
    EUROPEAN RESPIRATORY JOURNAL, 2021, 58
  • [6] Late Breaking Abstract - Two Phase 3 Randomized Clinical Trials of Gefapixant, a P2X3 Receptor Antagonist, in Refractory or Unexplained Chronic Cough (COUGH-1 and COUGH-2)
    McGarvey, Lorcan
    Birring, Surinder
    Morice, Alyn
    Dicpinigaitis, Peter
    Pavord, Ian
    Schelfhout, Jonathan
    Nguyen, Allison Martin
    Li, Qing
    Tzontcheva, Anjela
    Iskold, Beata
    Green, Stuart
    La Rosa, Carmen
    Muccino, David
    Smith, Jaclyn
    EUROPEAN RESPIRATORY JOURNAL, 2020, 56
  • [7] Design and rationale of two phase 3 randomised controlled trials (COUGH-1 and COUGH-2) of gefapixant, a P2X3 receptor antagonist, in refractory or unexplained chronic cough
    Muccino, David R.
    Morice, Alyn H.
    Birring, Surinder S.
    Dicpinigaitis, Peter, V
    Pavord, Ian D.
    Assaid, Christopher
    Kleijn, Huub Jan
    Hussain, Azher
    La Rosa, Carmen
    McGarvey, Lorcan
    Smith, Jaclyn A.
    ERJ OPEN RESEARCH, 2020, 6 (04) : 1 - 11
  • [8] Comorbid Conditions and Medical History Among Patients with Refractory or Unexplained Chronic Cough in Two Phase 3 Clinical Trials (COUGH-1 and COUGH-2)
    Dicpinigaitis, Peter
    Birring, Surinder
    McGarvey, Lorcan
    Morice, Alyn
    Pavord, Ian
    Smith, Jaclyn
    La Rosa, Carmen
    Li, Qing
    Nguyen, Allison Martin
    Schelfhout, Jonathan
    Tzontcheva, Anjela
    Muccino, David
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2021, 147 (02) : AB61 - AB61
  • [9] Rationale and Design of Two, Phase 3, Randomized Controlled Trials (COUGH-1 and COUGH-2) of Gefapixant, A P2x3 Receptor Antagonist, in Refractory and Unexplained Chronic Cough
    Muccino, D.
    Morice, A. H.
    Birring, S. S.
    McGarvey, L.
    Dicpinigaitis, P.
    Pavord, I. D.
    Tershakovec, A. M.
    Kitt, M. M.
    Zheng, Y.
    Assaid, C.
    Smith, J.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
  • [10] The Leicester Cough Questionnaire in two phase 3 trials of gefapixant in chronic cough
    Birring, Surinder S.
    Smith, Jaclyn A.
    Morice, Alyn
    Pavord, Ian
    Dicpinigaitis, Peter V.
    Mcgarvey, Lorcan
    Tzontcheva, Anjela
    Li, Qing
    Nguyen, Allison Martin
    Schelfhout, Jonathan
    Muccino, David
    La Rosa, Carmen
    EUROPEAN RESPIRATORY JOURNAL, 2021, 58
12345